Zobrazeno 1 - 10
of 335
pro vyhledávání: ''
Autor:
Maja Bech Juul, Jelena Jelicic, Pavithra Laxsen Anru, Henriette Engberg, Pernille Hammershøj Jensen, Helene Bjørg Kristensen, Joachim Baech, Michael Roost Clausen, Anne Ortved Gang, Lars Munksgaard, Tarec Christoffer El-Galaly, Henrik Frederiksen, Thomas Stauffer Larsen
Publikováno v:
Juul, M B, Jelicic, J, Anru, P L, Engberg, H, Hammershøj Jensen, P, Kristensen, H B, Baech, J, Clausen, M R, Gang, A O, Munksgaard, L, El-Galaly, T C, Frederiksen, H & Stauffer Larsen, T 2022, ' Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma : a Danish population-based cohort study ', Leukemia and Lymphoma, vol. 63, no. 9, pp. 2074-2083 . https://doi.org/10.1080/10428194.2022.2064982
Diffuse large B-cell lymphoma is an aggressive disease occurring primarily in elderly patients. Despite high curative rates with doxorubicin-containing treatment, some elderly patients receive less intensive treatments, mainly due to advanced age, co
Autor:
Lucile Bussot, Simon Chevalier, Caroline Algrin, Anouk Emadali, Laurence David-Boudet, Christine Lefebvre, Cyril Fournier, Laurent Martin, Claire Vettier, O. Casasnovas, Remy Gressin, Caroline Chapusot, Mary Callanan, Edwige Col, Thierry Bonnefoix, Marie-Christine Jacob, Anne McLeer, Antonin Bouroumeau, Tatiana Raskovalova, Hervé Sartelet
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 7, Iss 6, Pp 604-615 (2021)
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research
Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will relapse. Ove
Autor:
Wenqi Jiang, Li-Qin Ping, Qingqing Cai, Bing Bai, Xiaoxiao Wang, Jibin Li, Qixiang Rong, Jia-Ying Mao, Yan-Xia He, Haixia He, Cheng Huang, Yan Gao, Zhi Ming Li, He Huang, Huiqiang Huang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 21, Pp 7650-7664 (2021)
Cancer Medicine, Vol 10, Iss 21, Pp 7650-7664 (2021)
Purpose Some studies have indicated that using 500 mg/m2 rituximab combined with CHOP‐14 may be beneficial for elderly men but not women with diffuse large B‐cell lymphoma (DLBCL). The purpose of this study was to investigate the potential benefi
Autor:
M. Parrini, F. Simonetti, E. Banti, C. Camerini, L. Bozzoli, E. Sant’Antonio, V. Ciliberti, E. Capochiani, A. Ginori, M. Pellegri, C. De Gaudio
Publikováno v:
Tumori Journal. 107:NP127-NP130
Introduction: Posttransplant lymphoproliferative disorders (PTLDs) refer to a group of diseases, including diffuse large B-cell lymphoma (DLBCL), that develop after solid organ transplantation or hematopoietic stem cell transplantation. Extranodal in
Autor:
Marcello Ferreti Fanelli, Marcia Torresan Delamain, Fernando Augusto Soares, Carmen Silvia Passos Lima, Angelo Borsarelli Carvalho Brito, Carmino Antonio De Souza, José Vassallo
Publikováno v:
Tumor Biology. 43:129-140
OBJECTIVES: Single nucleotide variants (SNVs) in vascular endothelial growth factor A (VEGFA) and VEGFA receptor (KDR) genes confer different inherited abilities in angiogenesis (AG) pathway. We aimed in the present study to evaluate influence of six
Autor:
Yoko Inaguma, Eiichi Ohtsuka, Yukiyoshi Moriuchi, Kazuho Miyashita, Masashi Mizokami, Nobuhiko Yamauchi, Tadahiko Igarashi, Koji Izutsu, Hiroshi Gomyo, Nobuko Kubota, Ryuzo Ueda, Mio Kurata, Yoshiko Inoue, Yoshiko Atsuta, Rika Sakai, Norifumi Tsukamoto, Yoko Ushijima, Kisato Nosaka, Dai Maruyama, Sachiko Suzuki, Toshiki Uchida, Shinichiro Yoshida, Ilseung Choi, Shigeru Kusumoto, Go Yamamoto, Yasuhito Tanaka, Kensuke Kojima, Satoshi Ichikawa, Hideki Tsujimura
Publikováno v:
Cancer Science
We conducted a nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)‐positive patients with diffuse large B‐cell lymphoma (DLBCL) and 278 HBsAg‐negative patients with DLBCL, as a control cohort, who received r
Autor:
Shuvayu S Sen, Monika Raut, Dominique Lejeune, Guillaume Germain, François Laliberté, Philippe Armand, Xiaoqin Yang, Mei Sheng Duh, Kaushal Desai
Publikováno v:
The Oncologist
Background Diffuse large B‐cell lymphoma (DLBCL) represents the most common subtype of non‐Hodgkin lymphoma in the U.S., but current real‐world data are limited. This study was conducted to describe real‐world characteristics, treatment patte
Autor:
Hongying Pan, Xiangmin Tong, Shufang Xie, Chen Yang, Weimin Fan, Shibing Wang, Wen Lei, Yi Wu
Publikováno v:
Oncology Reports
Non‑Hodgkin lymphoma (NHL) is a form of lymphoid malignancy, with diffuse large B cell lymphoma (DLBCL) being the most common NHL isoform. Approximately half of patients with DLBCL are successfully cured via first‑line Rituximab, Cyclophosphamide
Autor:
Ping-Chiao Tsai, Zuguang Xia, Kai Xue, Fangfang Lv, Francisco J. Hernandez-Ilizaliturri, Junning Cao, Xiaojian Liu, Ye Guo, Cory Mavis, Yizhen Liu, Qunling Zhang, Xiaonan Hong, Juan J Gu, Ling Yang
Publikováno v:
Aging (Albany NY)
Intercellular adhesion molecule-1 (ICAM-1) is a cell-surface receptor contributing to lymphocyte homing, adhesion and activation. The prognostic significance of the protein is unknown in diffuse large B-cell lymphoma (DLBCL) in post-rituximab era. We
Autor:
Coreline N. Burggraaff, Gregor Verhoef, Otto S. Hoekstra, Marie José Kersten, Lidwine W. Tick, Mels Hoogendoorn, Margreet Oosterveld, Daphne de Jong, Nicole C. H. P. van der Burg-de Graauw, Marinus van Marwijk Kooy, Matthijs H Silbermann, Aart Beeker, Marjolein van der Poel, Bart de Keizer, Eva de Jongh, Jeanette K. Doorduijn, Harry R. Koene, Thomas Stauffer Larsen, Memis Y Bilgin, Lara H Böhmer, Joost W. J. van Esser, Peter de Nully Brown, Marcel Nijland, Maria B.L. Leijs, J.F.M. Pruijt, Anne I.J. Arens, Josée M Zijlstra-Baalbergen, Pieternella J. Lugtenburg, Kon-Siong G. Jie, Rolf E. Brouwer, King H. Lam, Rob Fijnheer, Bronno van der Holt, Francesco d'Amore
Publikováno v:
Journal of Clinical Oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38, 3377-3387
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418
Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38, 3377-3387
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418
PURPOSE Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab i